Literature DB >> 1417274

Acute rejection of lung allografts with various immunosuppressive protocols.

B P Griffith1, R L Hardesty, J M Armitage, R L Kormos, G C Marrone, S Duncan, I Paradis, J H Dauber, S A Yousem, P Williams.   

Abstract

Between February 1990 and December 1991, 69 patients who survived for a minimum of 5 days after single-lung (27), double-lung (32), or heart-lung transplantation (10) were studied to learn the incidence and severity of acute rejection and the possible effects of various immunosuppressive protocols on this rejection. Acute rejection was less common (2.1 versus 3.1 episodes/patient) after transplantation in those 30 candidates who received rabbit antithymocyte globulin for the first 5 postoperative days versus the 28 who were maintained on cyclosporine, azathioprine, and prednisone alone (p < 0.05), but no patient escaped at least one episode. Patients given cyclosporine received more 3-day courses of methylprednisolone (p < 0.02) than those given rabbit antithymocyte globulin (2.5 versus 1.7 courses). Although no disadvantage in terms of infectious morbidity was noted in the rabbit antithymocyte globulin group, no obvious intermediate advantage was noted in survival (85% at 12 months) or grade of rejection or airway flows. The most common histopathologic grades were mild (A2) and moderate (A3); the average grade was A2.3. FK 506 was tested in 11 patients, and early results are promising relative to low early and likely fewer late episodes of rejection. No differences were noted in the likelihood of rejection for any procedures.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1417274     DOI: 10.1016/0003-4975(92)90635-h

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  A decade of lung transplantation.

Authors:  B P Griffith; R L Hardesty; J M Armitage; B G Hattler; S M Pham; R J Keenan; I Paradis
Journal:  Ann Surg       Date:  1993-09       Impact factor: 12.969

2.  A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.

Authors:  B P Griffith; K Bando; R L Hardesty; J M Armitage; R J Keenan; S M Pham; I L Paradis; S A Yousem; K Komatsu; H Konishi
Journal:  Transplantation       Date:  1994-03-27       Impact factor: 4.939

3.  Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients.

Authors:  Gilbert J Burkart; Gerald C Smaldone; Michael A Eldon; Raman Venkataramanan; James Dauber; Adriana Zeevi; Kenneth McCurry; Teresa P McKaveney; Timothy E Corcoran; Bartley P Griffith; Aldo T Iacono
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.